Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

168 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T cell efficacy against solid malignancies.
Greco B, Malacarne V, De Girardi F, Scotti GM, Manfredi F, Angelino E, Sirini C, Camisa B, Falcone L, Moresco MA, Paolella K, Di Bono M, Norata R, Sanvito F, Arcangeli S, Doglioni C, Ciceri F, Bonini C, Graziani A, Bondanza A, Casucci M. Greco B, et al. Among authors: arcangeli s. Sci Transl Med. 2022 Jan 19;14(628):eabg3072. doi: 10.1126/scitranslmed.abg3072. Epub 2022 Jan 19. Sci Transl Med. 2022. PMID: 35044789
CAR T cell manufacturing from naive/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome.
Arcangeli S, Bove C, Mezzanotte C, Camisa B, Falcone L, Manfredi F, Bezzecchi E, El Khoury R, Norata R, Sanvito F, Ponzoni M, Greco B, Moresco MA, Carrabba MG, Ciceri F, Bonini C, Bondanza A, Casucci M. Arcangeli S, et al. J Clin Invest. 2022 Jun 15;132(12):e150807. doi: 10.1172/JCI150807. J Clin Invest. 2022. PMID: 35503659 Free PMC article.
Time to evolve: predicting engineered T cell-associated toxicity with next-generation models.
Donnadieu E, Luu M, Alb M, Anliker B, Arcangeli S, Bonini C, De Angelis B, Choudhary R, Espie D, Galy A, Holland C, Ivics Z, Kantari-Mimoun C, Kersten MJ, Köhl U, Kuhn C, Laugel B, Locatelli F, Marchiq I, Markman J, Moresco MA, Morris E, Negre H, Quintarelli C, Rade M, Reiche K, Renner M, Ruggiero E, Sanges C, Stauss H, Themeli M, Van den Brulle J, Hudecek M, Casucci M. Donnadieu E, et al. Among authors: arcangeli s. J Immunother Cancer. 2022 May;10(5):e003486. doi: 10.1136/jitc-2021-003486. J Immunother Cancer. 2022. PMID: 35577500 Free PMC article. Review.
Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia.
Tettamanti S, Rotiroti MC, Giordano Attianese GMP, Arcangeli S, Zhang R, Banerjee P, Galletti G, McManus S, Mazza M, Nicolini F, Martinelli G, Ivan C, Veliz Rodriguez T, Barbaglio F, Scarfò L, Ponzoni M, Wierda W, Gandhi V, Keating M, Biondi A, Caligaris-Cappio F, Biagi E, Ghia P, Bertilaccio MTS. Tettamanti S, et al. Among authors: arcangeli s. Leuk Lymphoma. 2022 Jul;63(7):1566-1579. doi: 10.1080/10428194.2022.2043299. Epub 2022 Mar 8. Leuk Lymphoma. 2022. PMID: 35259043 Free PMC article.
Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon System.
Rotiroti MC, Buracchi C, Arcangeli S, Galimberti S, Valsecchi MG, Perriello VM, Rasko T, Alberti G, Magnani CF, Cappuzzello C, Lundberg F, Pande A, Dastoli G, Introna M, Serafini M, Biagi E, Izsvák Z, Biondi A, Tettamanti S. Rotiroti MC, et al. Among authors: arcangeli s. Mol Ther. 2020 Sep 2;28(9):1974-1986. doi: 10.1016/j.ymthe.2020.05.021. Epub 2020 May 30. Mol Ther. 2020. PMID: 32526203 Free PMC article.
168 results